Incyte has dropped its lawsuit in exchange for the CMS agreeing not to classify its JAK inhibitor cream Opzelura as a line extension of Jakafi. More: Incyte drops lawsuit as CMS relents on classification of Opzelura Source: fierce
read more
Breakwater phase 3 data show significant gains in progression‑free survival More: Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC Source: News
read more
Sanofi therapy becomes first disability‑targeting medicine for nrSPMS More: Cenrifki approved in EU for secondary progressive multiple sclerosis Source: News
read moreAs a sweltering heat wave hit Europe, a swath of pharma companies and healthcare marketing agencies from around the world descended on southern France chasing a hot streak of their own. More: Novartis’ ‘Relax Your Tight End’ prostate cancer campaign
read more© 1994 - 2026 B.M. Pharmaceuticals